News Detail
Bagsværd, Denmark, 21 Oct 2024: As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the semaglutide drug showed it can provide heart-related benefits, too.
Oral semaglutide, sold as Ryb......
View Details
Source : Fierce Pharma
Novo Nordisk
cardiovascular outcomes
Rybelsus
GLP-1
semaglutide
clinical trial data
Clinical Data
Fierce Pharma Homepage
Pharma
Related News
- Police caught expired cosmetic goods in Meerut, DI denied action (09-11-2024)
- Sanitary napkins, baby diapers will now need BIS certification (09-11-2024)
- New Recruitment Rules for Medical Device Regulatory Positions (09-11-2024)
- Accused caught with 400 Pregabalin capsule handed over to DCO for further action (09-11-2024)
- Telangana DCA seize narcotic drugs, psychotropic substances from private hospitals (09-11-2024)
- Govt launches Rs 500 crore scheme to strengthen medical device industry (09-11-2024)
- Baddi firm asked to stop narcotic drug production amid CID probe (09-11-2024)
- Mohali police bust unit producing fake medicine (09-11-2024)
- Delhi HC restrains Aquakind labs from using 'AQUAKIND' trademark (09-11-2024)
- MBBS from abroad, started practicing medicine without passing FMGE, Registrations cancelled (08-11-2024)